Argenx Se (ARGX) Non-Current Assets (2015 - 2025)
Argenx Se (ARGX) posted Non-Current Assets of $1.8 billion for Q4 2025, up 100.03% on a QoQ basis from -$5829.7 billion in Q2 2025, and up 35.18% year-over-year from $1.3 billion in Q4 2024.
Argenx Se (ARGX) Non-Current Assets (2015 - 2025) Analysis & Trends
Argenx Se's Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.8 billion for Q4 2025.
- Quarterly Non-Current Assets rose 35.18% year-over-year to $1.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5826.4 billion (changed N/A YoY) and the FY2025 annual result came in at $1.8 billion, up 35.18% from the prior year.
- Non-Current Assets was $1.8 billion for Q4 2025 at Argenx Se, up from -$5829.7 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.8 billion in Q4 2025 and bottomed at -$5829.7 billion in Q2 2025.
- A 5-year average of -$582.4 billion and a median of $389.4 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets jumped 387.53% — and 2025, when it sank 1094330.5%.
- Argenx Se's Non-Current Assets stood at $307.3 million in 2021, then advanced by 17.17% to $360.1 million in 2022, then increased by 16.29% to $418.7 million in 2023, then surged by 215.11% to $1.3 billion in 2024, then soared by 35.18% to $1.8 billion in 2025.
- Business Quant data shows ARGX's Non-Current Assets at $1.8 billion in Q4 2025, -$5829.7 billion in Q2 2025, and $1.3 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 285.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 910.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.78 Bn |
| Jun 30, 2025 | -5,829.73 Bn |
| Dec 31, 2024 | 1.32 Bn |
| Jun 30, 2024 | 532.77 Mn |
| Dec 31, 2023 | 418.72 Mn |
| Jun 30, 2023 | 502.28 Mn |
| Dec 31, 2022 | 360.06 Mn |
| Jun 30, 2022 | 319.95 Mn |
| Dec 31, 2021 | 307.30 Mn |
| Jun 30, 2021 | 348.36 Mn |
| Dec 31, 2020 | 216.26 Mn |
| Jun 30, 2020 | 71.45 Mn |
| Dec 31, 2019 | 66.55 Mn |
| Jun 30, 2019 | 55.35 Mn |
| Dec 31, 2018 | 6.87 Mn |
| Jun 30, 2018 | 5.08 Mn |
| Dec 31, 2017 | 4.83 Mn |
| Jun 30, 2017 | 3.93 Mn |
| Dec 31, 2016 | 4.30 Mn |
| Dec 31, 2015 | 2.00 Mn |